Agent for prophylactic and/or therapeutic treatment of diabetes
According to the present invention, an agent for prophylactic and/or therapeutic treatment of diabetes comprising a substance inhibiting activity of farnesoid X receptor as an active ingredient can be provided.
1 - 22 . (canceled)
23 . A method for inhibiting liver gluconeogenesis, which comprises administering to a patient in need thereof a substance which inhibits activity of a farnesoid X receptor as an active ingredient.
24 . A method for prophylactic and/or therapeutic treatment of a disease resulting from a decrease in energy metabolism, which comprises administering to a patient in need thereof a substance which inhibits activity of a farnesoid X receptor as an active ingredient.
25 . The method according to claim 24 , wherein the decrease in energy metabolism is a decrease in basal metabolism.
26 . The method according to claim 24 , wherein the decrease in energy metabolism is a decrease in thermogenesis.
27 . The method according to claim 23 or 24 , wherein the substance which inhibits activity of the farnesoid X receptor is a substance which increases an expression level of a gene encoding cholesterol 7α hydroxylase.
28 . The method according to claim 23 or 24 , wherein the substance which inhibits activity of the farnesoid X receptor is a substance which decreases an expression level of a gene encoding a small heterodimer partner.
29 . The method according to claim 23 or 24 , wherein the substance which inhibits activity of the farnesoid X receptor is a pharmaceutically acceptable anion exchange resin or a farnesoid X receptor antagonist.
30 . The method according to claim 23 or 24 , wherein the substance which inhibits activity of the farnesoid X receptor is a pharmaceutically acceptable anion exchange resin.
31 . The method according to claim 30 , wherein the pharmaceutically acceptable anion exchange resin has a bile acid-adsorbing ability.
32 . The method according to claim 30 , wherein the pharmaceutically acceptable anion exchange resin is selected from colestimide, cholestyramine resin, colestipol, sevelamer hydrochloride, and colesevelam hydrochloride.
33 . The method according to claim 30 , wherein the pharmaceutically acceptable anion exchange resin is an anion exchange resin synthesized by a polymerization reaction of an epichlorohydrin derivative and an amine.
34 . The method according to claim 30 , wherein the pharmaceutically acceptable anion exchange resin is colestimide.
35 . The method according to claim 33 , wherein the amine is an imidazole derivative.